MedTrace Logo

Drug-drug Interaction of BI 201335 and Microgynon

NCT01570244 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-08-03

Study results available
· View outcomes & findings →

Summary

This study will investigate possible effect of multiple oral doses of BI 201335 on the steady state pharmacokinetics of ethinylestradiol and levonogestrel

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

levonorgestrel

multiple doses

DRUG

Ethinylestradiol

multiple doses

DRUG

levonorgestrel

multiple doses

DRUG

BI 201335

multiple doses

DRUG

Ethinylestradiol

multiple doses

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01570244 on ClinicalTrials.gov